The Medicines Company, Boston Scientific announce co-promotion agreement for Promus PREMIER stent system

NewsGuard 100/100 Score

Boston Scientific Corporation (NYSE: BSX) and The Medicines Company (NASDAQ: MDCO) announce a co-promotion agreement for the Boston Scientific Promus PREMIER™ Everolimus-Eluting Platinum Chromium Coronary Stent System. Under the terms of the agreement, The Medicines Company's acute cardiovascular care sales force will collaborate with the Boston Scientific Interventional Cardiology sales force to provide promotional support for the Promus PREMIER Stent System in U.S. hospitals beginning January 1, 2014.

The Promus PREMIER Stent System, the latest Boston Scientific FDA-approved drug-eluting stent (DES), offers physicians improved performance in treating patients with coronary artery disease.  It features a unique, customized platinum chromium alloy stent architecture, combined with the market-leading Everolimus drug, a biocompatible, fluorinated co-polymer, and an enhanced stent delivery system. Coronary artery disease is a narrowing of blood vessels that supply blood and oxygen to the heart.  Patients with coronary artery disease may experience chest pain, shortness of breath and fatigue, and may also be at risk for a heart attack. One established treatment option is the placement of a stent in the artery to help keep it open and allow the blood to flow more freely.

"The Medicines Company's established and highly complementary product portfolio in interventional cardiology will enhance the capabilities of our sales force as we introduce the Promus PREMIER System in the U.S. market," said Matt Franklin, vice president, Interventional Cardiology Global Marketing, Boston Scientific. "This collaborative agreement brings together two of the market leading providers of interventional cardiology and acute care solutions to better support our customers and the patients they serve."

"Our goal in entering into this agreement with Boston Scientific is to help improve patient care with a comprehensive suite of solutions for acute cardiovascular care," said Brent Furse, senior vice president and chief customer officer of The Medicines Company.  "This intensifies our efforts to save lives, alleviate suffering and contribute to the economics of healthcare by serving leading hospitals."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New studies underscore the importance of inclusive approaches in peripheral artery disease treatment